# Onconetics Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onconetics-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.onconetics.com
- Latest round: Seed (Sep 25, 2017)
- Investors on record: 2

## About

Onconetics Pharmaceuticals, Inc. is a biotech company focused on developing innovative therapies for cancer treatment using proprietary technologies and advanced drug formulations.Onconetics Pharmaceuticals, Inc. specializes in creating targeted cancer therapies. Founded in 2016 in San Francisco, US, the company has undergone strategic developments to enhance its operational focus. Luke Gruenert serves as the CEO and founder of the company, marking his leadership with experience from previous ventures. In September 2017, Onconetics raised seed funding from IndieBio and SOSV, marking its first investment round.Onconetics Pharmaceuticals, Inc. is committed to developing advanced cancer therapies that leverage innovative drug delivery mechanisms and formulation technologies. Their focus lies in precision medicine solutions aimed at improving treatment outcomes for patients with various forms of cancer. The company works closely with academic institutions and research organizations to validate their therapeutic approaches and maintain a competitive edge in the biotechnology sector.Onconetics Pharmaceuticals, Inc. primarily operates on a funding-based model due to its focus on research and development in the pharmaceutical sector. The company’s revenue structure is influenced by its funding rounds, with the 2017 seed funding likely supporting its ongoing research initiatives and operational costs as it develops its product pipeline.Onconetics Pharmaceuticals, Inc. aims to launch new cancer therapy products by 2025, focusing on enhancing their drug formulations and expanding their pipeline. The company plans to enter new markets in North America and Europe, targeting regions with high cancer prevalence. The seed funding raised in September 2017 will be allocated to support clinical trials and product development, ensuring that Onconetics can effectively address unmet medical needs in cancer treatment.

## Funding rounds

- Seed, Sep 25, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed